Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

TORM purchases eight MR product tankers with chemical trading capabilities from TEAM Tankers in a partly share-based transaction

TORM has today entered into an agreement to purchase eight 2007-2012 built MR product tanker vessels from TEAM Tankers Deep Sea Ltd. for a total cash consideration of USD 82.5m and the issuance of 5.97 million shares. The transaction will increase TORM’s total fleet to 83 vessels on a fully delivered basis. The vessels are all built at the Croatian shipyard Brodotrogir and have high technical specifications with six of the vessels having specialized cargo tank configurations and extended tank segregations (IMO 2), allowing for enhanced trading flexibility through chemical trading options,

Helsinki Airport wins two awards: best airport in Europe in its size category and recognition for hygiene measures during COVID-19

Airports Council International, ACI, awarded the Airport Service Quality Award to Helsinki Airport, rating it the best airport in Europe in its size category (15–25 million passengers) in 2020.Helsinki Airport was selected as the best European airport in its size category in 2020. The Airport Service Quality Award (ASQ) was rewarded by Airports Council International (ACI).  Helsinki airport also received recognition for its hygiene measures during the COVID-19 pandemic in 2020. “Serving passengers and maintaining a premium customer experience are of primary importance to us also in times

Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development

Dr Korsgren to lead the research and development of Hansa’s proprietary enzyme technology platform as the Company expands also into new therapeutic areasLund, Sweden March 1, 2021. Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces the appointment of Magnus Korsgren, M.D., Ph.D. as Vice President and Head of Research and Development. Dr Korsgren will lead the efforts to advance Hansa Biopharma’s pipeline of drug candidates for rare immunologic diseases based on the Company’s proprietary IgG-cleaving enzyme technology

EG7 Completes the Acquisition of Piranha Games Inc.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE READ "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. PRESS RELEASE Stockholm, 1 March 2021 Enad Global 7 AB (publ) (“EG7” or the “Company”) has completed the acquisition of 100 percent of the shares in Piranha Games Inc. (“Piranha Games”),

Etteplan introduces HowTo, a digital leap in the creation and distribution of technical information

Etteplan Press release March 1, 2021 at 9.00 a.m. EET Etteplan today announced the global commercial availability of Etteplan HowTo, a completely new cloud-based service for efficient creation, secure hosting and on-demand multi-channel distribution of technical information for industrial equipment and other needs of the manufacturing industry.  Etteplan HowTo, an end-to-end service enables smooth translations, instantly distributed modifications, and agile repurposing for new needs of technical information. Etteplan HowTo structures and stores digital technical information in the

Proact launches updated disaster recovery solution for multicloud environments

Proact is launching a new version of its managed disaster recovery service, which allows customers to continue operating their businesses following disruptive events, regardless of where their data is located.Proact’s new and updated disaster recovery solution protects data from customers’ data centres, from Proact’s newly updated PHC (Proact Hybrid Cloud) platform and from business servers sitting in public cloud platforms, such as AWS and Azure. In addition, the updated disaster recovery service covers customer data in physical servers and clusters, and in volumes within NetApp filers.

Image campaign 'Don’t be a fossil fool!'

‘Don’t be a fossil fool!’ – that is the daring title of Industrial Solar GmbH’s current campaign. The goal is to prompt ‘fossil fools’, namely different sectors of industry, to rethink their consumption of fossil fuels and to change to renewable energy sources instead. The campaign started in mid-February 2021 and is run on the social media accounts Instagram, twitter and LinkedIn.Industrial Solar GmbH is a 100% subsidiary of Industrial Solar Holding Europe AB and a leading turnkey provider of customized renewable energy solutions with the vision to decarbonize industry. With its broad

Notice to the annual general meeting in Bonava AB (publ)

Shareholders of Bonava AB (publ) ("Bonava"), are hereby invited to attend the annual general meeting, to be held on Wednesday, 31 March 2021. Due to the COVID-19 pandemic, the meeting will be carried out only through postal voting in accordance with the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations. It will not be possible to attend the meeting in person or by proxy.Shareholder's right to request information The shareholders have the right to receive information from the board of directors and CEO regarding

Oncorena Receives Approval of First in Patient Trial with Orellanine as a Potential Breakthrough Therapy in Metastatic Renal Cancer Patients

LUND, SWEDEN, March 1, 2021 - Oncorena, dedicated to developing a unique and potential breakthrough therapy for metastatic renal cancer, today announces the Swedish Medical Products Agency’s approval of the Phase 1/2 of First in Patient trial of the first-in-class compound, orellanine in patients with metastatic renal cancer in dialysis.Preclinical evidence shows that orellanine, a well known fungus toxin, specifically exerts powerful anti-tumor effects on metastatic renal cancer in different preclinical models. Orellanine has a unique mode of action. All preclinical activities have been

SBB's offer to the shareholders of Entra – Expiry of acceptance period and non-fulfilment of the minimum acceptance condition

Reference is made to the combined offer document and exempted document dated 20 January 2021 (the "Offer Document") for the voluntary offer by Samhällsbyggnadsbolaget i Norden AB ("SBB") to acquire all outstanding shares in Entra ASA ("Entra") (the "Offer"). Under the terms of the Offer, Entra shareholders are offered a fixed price of NOK 190.00 per Entra share, delivered as NOK 123.50 in cash (65% of the total consideration) and NOK 66.50 in new SBB Class B Shares (35% of the total consideration). The acceptance period for the Offer expired on 26 February 2021 at 16:30 hours (CET).

Nordea has published its Annual Report, Sustainability Report and Remuneration Report for Governing Bodies

Nordea Bank AbpStock exchange release – Annual Financial Report1 March 2021 at 9.00 EETNordea has today published its Annual Report for the financial year 2020, which includes the audited Financial Statements, the Board of Directors’ Report and the Corporate Governance Statement. Further, Nordea has today published its Sustainability Report and its Remuneration Report for Governing Bodies for year 2020. The Annual Report can be downloaded at nordea.com . Nordea has also published the

Stora Enso Oyj's share-based long-term incentive plan for 2021 – 2023

STORA ENSO OYJ STOCK EXCHANGE RELEASE 1 March 2021 at 9.00 EETStora Enso is launching a new plan for 2021–2023 under its share-based long-term incentive programme. The purpose of the plan is to incentivise and align management with shareholder interests and the long-term strategy of the Company. This is done through setting measurable financial long-term targets as well as through encouraging personal share ownership.The long-term share incentive plan consists of performance shares with a three-year performance period as well as restricted shares with a three-year retainment period, which

NOTICE TO THE ANNUAL GENERAL MEETING OF KONECRANES PLC

KONECRANES PLC STOCK EXCHANGE RELEASE 1 MARCH 2021 at 09:00 EET NOTICE TO THE ANNUAL GENERAL MEETING OF KONECRANES PLC Notice is given to the shareholders of Konecranes Plc (“Konecranes” or the “Company”) to the Annual General Meeting to be held on Tuesday 30 March 2021 at 10.00 am at the Company’s address at Keilaranta 13 A, 02150 Espoo, Finland. The shareholders of the Company and their proxy representatives may participate in the meeting and exercise their shareholder rights only by voting in advance, by making counterproposals in advance and asking questions in advance in

Aqilion strengthens its operational team in line with the company’s research strategy

Aqilion announced today that Johan Lund, the current Chairman of the company, will join the operational team as Chief Scientific Officer beginning on March 1. Johan Lund will mainly contribute his expertise in the field of inflammation research, which is Aqilion’s research priority. During its journey of change, Aqilion has transitioned from being a company that invested in startup companies to launching wholly owned projects with potential to break new ground in the development of innovative therapies. The company is focusing on novel therapies for patients with diseases primarily in

Lakers expands into the UK through acquisition of entry platform Pump Supplies Ltd

Oslo 1 March 2021 – Lakers Group  (“Lakers”), the leading independent water pump service company in the Nordic region, has expanded its presence into the United Kingdom through an acquisition of Pump Supplies Ltd . The acquisition will take Lakers annual revenue to ca. NOK 900 million.“We are delighted to have Pump Supplies joining our group. Pump Supplies has a really strong market position, fantastic people and shares the same dedication towards their customers as the rest of our companies,” says Carl-Johan Callenholm, CEO Lakers.

Solteq Plc acquires Partiture’s professional services business specialized in the utilities sector

Stock Exchange BulletinMarch 1, 2021 at 08:00 a.m.Solteq Plc has today signed a business transfer agreement, whereby Partiture Oy’s professional services business, along with its current employees and customers, will be transferred to Solteq. The agreement is effective as of March 1, 2021. Partiture Oy is Finland’s leading consulting and project management company in the energy sector. Utilities sector is one of the Solteq’s key drivers for growth in the Nordics, where digital disruption has placed digital solutions at the core of companies’ strategies. As a result of the business

Hexagon Agility receives additional order from major global logistics customer for CNG trucks

Hexagon Agility, a business of Hexagon Composites, signed a master services agreement in June 2020 with a global logistics customer to deliver compressed natural gas (CNG) fuel systems for medium and heavy-duty trucks. The first order received related to this customer in 2021 represents an estimated total value of USD $6.8 million (approx. NOK 58 million).   As a low carbon fuel, CNG can result in reductions of greenhouse gas (GHG) emissions compared to diesel of over 20% when using conventional natural gas, or 90% or more when using renewable natural gas (RNG) produced from landfills,

SaltX enters new partnership to scale up and optimize the charging reactor

SaltX Technology - listed on Nasdaq First North- has entered a partnership agreement with the Australian company Calix Limited that develops pioneering technology for calcination processes. Together, the companies are now developing a charging reactor to optimize SaltX energy storage solution with new scalable technology to fit SaltX core technology and nanocoated salt.The reactor will be installed at SaltX current pilot in Stockholm and a complete optimized storage solution will be possible to test and validate during 2021.  ‘’We are thrilled to have a leading partner like Calix for

President and CEO of Caverion Corporation to change

Caverion Corporation     Inside information     28 February 2021 at 9.00 p.m. EETPresident and CEO of Caverion Corporation to change The Board of Directors of Caverion Corporation and President and CEO, Ari Lehtoranta, have today mutually agreed that Ari Lehtoranta will leave his position as President and CEO of Caverion Corporation. The Board of Directors of Caverion Corporation has appointed the Chairman of the Board of Directors, Mats Paulsson, as interim President and CEO effective today. Mats Paulsson will continue in his position as the Chairman of the Board of Directors. The

European Lingerie Group AB publishes unaudited 12 Months and Fourth Quarter 2020 Report

European Lingerie Group AB publishes unaudited 12 Months and Fourth Quarter 2020 Report (January 1 – December 31, 2020), including condensed interim consolidated financial statements.ELG is pleased to publish its 12 months and fourth quarter 2020 report. “Despite a very challenging year behind us when our business was hit by COVID-19 impact we are pleased to announce that the overall business decreased by 17.8% showing a relatively good resistance towards negative external factors. The business diversification into various markets, our various segments as well as distribution channels

Change in the number of votes in Tele2

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) today announced that Tele2’s total number of votes has decreased.Owners of 6,177 class A shares in Tele2 have requested the conversion of these to class B shares in accordance with the reclassification provision set forth in § 5 of Tele2’s articles of association. As of 26 February 2021, the total number of shares in Tele2 amounts to 690,341,597 of which 22,552,163 are class A shares with ten votes each, 667,789,434 are class B shares with one vote each. The total number of votes in Tele2 amounts to 893,311,064.For

BONESUPPORT’s FDA notification: Approval on DeNovo pathway for CERAMENT G will require additional data and clarifications

Lund, Sweden, 14:30 CET, 27 02 21 –BONESUPPORT ™, a leading company active in orthobiology for the treatment of skeletal injuries, today announced that the company has received a notification from the US Food and Drug Administration (FDA) that the company’s DeNovo application for CERAMENT G for bone infections can not be concluded without additional data and clarifications.   "We had obviously hoped to launch CERAMENT G in the US, for the indication bone infections, during the spring 2021, but the approval process with CERAMENT G being “the first of its kind”, will require additional

Josemaria Share Capital and Voting Rights Update

VANCOUVER, BC, February 26, 2021 /CNW/ - Josemaria Resources Inc. (TSX: JOSE) (OMX: JOSE) (OTCQB: JOSMF) ("Josemaria Resources" or the "Company") reports that, in accordance with the Swedish Financial Instruments Trading Act, as a result of the issuance of common shares pursuant to the terms of previously announced credit facilities, the number of issued and outstanding shares of the Company has increased to 302,593,209 common shares with voting rights as at February 28, 2021. Additional Information This is information that the Company is obliged to make public pursuant to the Swedish

FDA approves Oncopeptides' PEPAXTO® ( melphalan flufenamide) for patients with relapsed or refractory multiple myeloma

STOCKHOLM — February 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration, FDA, has approved PEPAXTO[®] (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory

There are no items matching the current filter
There are no more items matching the current filter
Back to top